These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 29718095)

  • 1. Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial.
    Fokas E; Fietkau R; Hartmann A; Hohenberger W; Grützmann R; Ghadimi M; Liersch T; Ströbel P; Grabenbauer GG; Graeven U; Hofheinz RD; Köhne CH; Wittekind C; Sauer R; Kaufmann M; Hothorn T; Rödel C;
    Ann Oncol; 2018 Jul; 29(7):1521-1527. PubMed ID: 29718095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor Regression Grading After Preoperative Chemoradiotherapy as a Prognostic Factor and Individual-Level Surrogate for Disease-Free Survival in Rectal Cancer.
    Fokas E; Ströbel P; Fietkau R; Ghadimi M; Liersch T; Grabenbauer GG; Hartmann A; Kaufmann M; Sauer R; Graeven U; Hoffmanns H; Raab HR; Hothorn T; Wittekind C; Rödel C;
    J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial.
    Hofheinz RD; Arnold D; Fokas E; Kaufmann M; Hothorn T; Folprecht G; Fietkau R; Hohenberger W; Ghadimi M; Liersch T; Grabenbauer GG; Sauer R; Rödel C; Graeven U;
    Ann Oncol; 2018 Aug; 29(8):1793-1799. PubMed ID: 29873684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Treatment Adherence With Oncologic Outcomes for Patients With Rectal Cancer: A Post Hoc Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial.
    Diefenhardt M; Ludmir EB; Hofheinz RD; Ghadimi M; Minsky BD; Rödel C; Fokas E
    JAMA Oncol; 2020 Sep; 6(9):1416-1421. PubMed ID: 32644104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome after total neoadjuvant treatment (CAO/ARO/AIO-12) versus intensified neoadjuvant and adjuvant treatment (CAO/ARO/AIO-04) a comparison between two multicenter randomized phase II/III trials.
    Diefenhardt M; Fleischmann M; Martin D; Hofheinz RD; Piso P; Germer CT; Hambsch P; Grützmann R; Kirste S; Schlenska-Lange A; Ghadimi M; Rödel C; Fokas E;
    Radiother Oncol; 2023 Feb; 179():109455. PubMed ID: 36572280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of neoadjuvant rectal score in prognosis and adjuvant chemotherapy decision-making in locally advanced rectal cancer following neoadjuvant short-course radiotherapy and consolidation chemotherapy].
    Zeng Q; Tang Y; Zhou HT; Li N; Liu WY; Chen SL; Li S; Lu NN; Fang H; Wang SL; Liu YP; Song YW; Li YX; Jin J
    Zhonghua Zhong Liu Za Zhi; 2024 Apr; 46(4):335-343. PubMed ID: 38644269
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic Significance of Neoadjuvant Rectal Score and Indication for Postoperative Adjuvant Therapy in Rectal Cancer Patients After Neoadjuvant Chemoradiotherapy.
    Maeda K; Shibutani M; Tachimori A; Nishii T; Aomatsu N; Fukuoka T; Nagahara H; Otani H; Inoue T; Ohira M
    In Vivo; 2020; 34(1):283-289. PubMed ID: 31882490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial.
    Fokas E; Liersch T; Fietkau R; Hohenberger W; Beissbarth T; Hess C; Becker H; Ghadimi M; Mrak K; Merkel S; Raab HR; Sauer R; Wittekind C; Rödel C
    J Clin Oncol; 2014 May; 32(15):1554-62. PubMed ID: 24752056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO-04 randomized phase 3 rectal cancer trial.
    Diefenhardt M; Hofheinz RD; Martin D; Beißbarth T; Arnold D; Hartmann A; von der Grün J; Grützmann R; Liersch T; Ströbel P; Grabenbauer GG; Rieger M; Fietkau R; Graeven U; Weitz J; Folprecht G; Ghadimi M; Rödel F; Rödel C; Fokas E;
    Int J Cancer; 2019 Oct; 145(8):2282-2291. PubMed ID: 30868576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of life in rectal cancer patients with or without oxaliplatin in the randomised CAO/ARO/AIO-04 phase 3 trial.
    Kosmala R; Fokas E; Flentje M; Sauer R; Liersch T; Graeven U; Fietkau R; Hohenberger W; Arnold D; Hofheinz RD; Ghadimi M; Ströbel P; Staib L; Grabenbauer GG; Folprecht G; Kirste S; Uter W; Gall C; Rödel C; Polat B;
    Eur J Cancer; 2021 Feb; 144():281-290. PubMed ID: 33383348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12.
    Fokas E; Allgäuer M; Polat B; Klautke G; Grabenbauer GG; Fietkau R; Kuhnt T; Staib L; Brunner T; Grosu AL; Schmiegel W; Jacobasch L; Weitz J; Folprecht G; Schlenska-Lange A; Flentje M; Germer CT; Grützmann R; Schwarzbach M; Paolucci V; Bechstein WO; Friede T; Ghadimi M; Hofheinz RD; Rödel C;
    J Clin Oncol; 2019 Dec; 37(34):3212-3222. PubMed ID: 31150315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
    Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
    J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes of elderly patients receiving neoadjuvant chemoradiation for locally advanced rectal cancer.
    Jiang DM; Raissouni S; Mercer J; Kumar A; Goodwin R; Heng DY; Tang PA; Doll C; MacLean A; Powell E; Price-Hiller J; Monzon J; Cheung WY; Vickers MM
    Ann Oncol; 2015 Oct; 26(10):2102-6. PubMed ID: 26232491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Capecitabine (Xeloda) vs. Combination of Capecitabine and Oxaliplatin (XELOX) as Neoadjuvant CRT for Locally Advanced Rectal Cancer.
    Yaghobi Joybari A; Azadeh P; Babaei S; Hosseini Kamal F
    Pathol Oncol Res; 2019 Oct; 25(4):1599-1605. PubMed ID: 30712194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
    Bosset JF; Calais G; Mineur L; Maingon P; Stojanovic-Rundic S; Bensadoun RJ; Bardet E; Beny A; Ollier JC; Bolla M; Marchal D; Van Laethem JL; Klein V; Giralt J; Clavère P; Glanzmann C; Cellier P; Collette L;
    Lancet Oncol; 2014 Feb; 15(2):184-90. PubMed ID: 24440473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma.
    Margalit O; Mamtani R; Kopetz S; Yang YX; Lawrence YR; Abu-Gazala S; Reiss KA; Golan T; Halpern N; Aderka D; Giantonio B; Shacham-Shmueli E; Boursi B
    Oncologist; 2019 Aug; 24(8):e671-e676. PubMed ID: 30696723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Retrospective study of role of neoadjuvant rectal scores in evaluating the 10-year disease-free survival of patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiotherapy followed by surgery].
    Zhang WL; Zhou C; Wang WF; Li WH; He JH; Lu ZH; Wu XJ; Lin JZ; Peng JH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Jun; 27(6):608-614. PubMed ID: 38901994
    [No Abstract]   [Full Text] [Related]  

  • 19. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
    Sauer R; Liersch T; Merkel S; Fietkau R; Hohenberger W; Hess C; Becker H; Raab HR; Villanueva MT; Witzigmann H; Wittekind C; Beissbarth T; Rödel C
    J Clin Oncol; 2012 Jun; 30(16):1926-33. PubMed ID: 22529255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can clinicopathological parameters predict for lymph node metastases in ypT0-2 rectal carcinoma? Results of the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 phase 3 trials.
    von den Grün JM; Hartmann A; Fietkau R; Ghadimi M; Liersch T; Hohenberger W; Weitz J; Sauer R; Wittekind C; Ströbel P; Rödel C; Fokas E;
    Radiother Oncol; 2018 Sep; 128(3):557-563. PubMed ID: 29929861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.